Eli Lilly and Company

Marlene L Cohen

David W Robertson

John M Schaus

James E Audia

William B Lacefield

Dennis C Thompson

David L Nelson

Ray W Fuller

William L Garbrecht

Jaswant S Gidda

Kirk Willis Johnson

Kathleen R Whitten

Thomas M Wilson

Lee A Phebus

Steven Swanson

John T Catlow

Theresa A Branchek

Michael J Martinelli

Daniel Joseph Cushing

Louis Lemberger

Michael O Martinelli

Mark J Goldberg

Compounds of formula I: ##STR1## are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.

5-HT.sub.4 agonists and antagonists

This invention provides a method for the treatment or amelioration of the symptoms of venomous bites or stings which comprises administering to a mammal in need thereof one or more 5-HT.sub.2 antagonists.

Methods of treating or ameliorating the symptoms of venomous bites and

Method for using ergoline compounds to effect physiological and

A method for antagonizing or blocking calcium channels in vascular tissue, comprising administering to an animal in need thereof a pharmaceutically-effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, --CO--(C.sub.1 -C.sub.6 alkyl), or --CH.sub.2 Ar, --CO--Ar, wherein Ar is phenyl or substituted phenyl;

Calcium channel antagonists

Indazolecarboxamides are used as antagonists and partial agonists for the serotonin receptor 5-HT.sub.4 and provide therapeutic methods for treatment of disorders caused by or affected by dysfunction of the 5-HT.sub.4 receptor.

Indazolecarboxamides

Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.

Serotonin agonist in combination with a tachykinin receptor antagonist

The present invention provides (8.beta.)-N-substituted cyclo or bicycloalkyl-6-(substituted)-ergoline-8-carboxamides useful for occupying 5HT.sub.2 or 5HT.sub.1.sbsb.c receptors in mammals. The invention also provides methods for treating a variety of disorders and conditions related to or affecting these receptors as well as pharmaceutical formulations of the compounds of the invention.

Substituted cyclo or bicycloalkylamides of (8.beta.)-6-(substituted)

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

Method for treating 5-HT.sub.2B receptor related conditions

The present invention provides a method for the treatment of migraine with compounds or compositions that are selective agonists of 5-HT.sub.1F receptors relative to other serotonin receptors that produce unwanted effects like vasoconstriction. The neurogenic meningeal extravasation that leads to the pain of migraine is inhibited.

5-HT.sub.1F mediated inhibition of neurogenic meningeal extravasation: a

Method for treating 5HT.sub.2B receptor related conditions

N-unsubstituted ergolines specifically bind to human 5-HT.sub.2 receptors, and are thus useful in treating diseases such as depression, hypertension and migraine.

Method of blocking human 5-hydroxytryptamine-2 receptors

This invention provides bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.

Growing community of inventors

Carmel, IN, United States of America

Marlene L Cohen